향후 수년간 발작적 운동실조증 치료제 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 6.5%로 152억 1,000만 달러로 성장합니다. 예측 기간 중의 성장은 유전학적 검사에 대한 접근성 증가, 유전 상담 서비스에 대한 수요 증가, 임상시험 수 증가, 환자 등록 수 증가, 희귀질환 바이오뱅크에 대한 투자 증가 등에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 기술 발전, 맞춤형 의료, 원격의료, 줄기세포 치료, 원격 재활 서비스 등을 들 수 있습니다.
신경질환의 유병률 증가는 발작적 운동실조증 치료제 시장의 성장을 가속할 것으로 예상됩니다. 신경질환에는 뇌, 척수, 뇌신경 및 말초신경, 자율신경계, 신경근, 신경근접합부, 근육을 포함한 중추신경계 및 말초신경계에 영향을 미치는 질환이 포함됩니다. 고령화, 유전적 소인, 감염 등의 요인이 신경질환의 이환율 상승에 기여하고 있습니다. 간헐적 운동실조 치료는 간헐적인 협응운동과 평형감각 상실을 동반하는 증상에 대한 대응과 관리를 강화하는 것을 목표로 하고 있습니다. 예를 들어 2022년 4월 벨기에에 본부를 둔 비영리 단체인 European Brain Council은 2022년 유럽에서 치매(진행성 신경질환)가 1,050만 명에게 영향을 미치고, 2050년에는 1,870만 명으로 증가할 것이라는 예측을 보고했습니다. 그 결과, 신경질환의 유병률 증가로 인해 발작적 운동실조증 치료제 시장에 박차를 가하고 있습니다.
발작적 운동실조증 치료제 시장의 주요 기업은 환자의 예후를 개선하고 이 희귀 신경질환의 미충족 수요를 충족시키기 위해 프리드리히 운동실조증(FA) 치료와 같은 혁신적인 솔루션 개발에 우선순위를 두고 있습니다. 삽화형 운동실조증(EA)은 산발적인 운동실조와 자발적 근육 협응 운동의 결여를 특징으로 하며, 다양한 기간, 빈도, 중증도를 가집니다. 예를 들어 2024년 2월 미국 생명공학 기업 Biogen Inc.는 프리드리히 실조증(FA) 치료제로 SKYCLARYS(오마벨록솔론)의 승인을 발표했습니다. 오마벨록솔론은 FA와 관련된 근본적인 미토콘드리아 기능 장애를 표적으로 삼아 단순히 증상을 완화하는 것뿐만 아니라 질병의 진행을 변화시킬 수 있습니다. 이 치료제는 강력한 전사 조절제 역할을 하여 미토콘드리아 기능과 세포 에너지 생산의 회복을 돕습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 발작적 운동실조증 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 발작적 운동실조증 치료 시장 : 성장률 분석
- 세계의 발작적 운동실조증 치료 시장 실적 : 규모와 성장, 2019-2024
- 세계의 발작적 운동실조증 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 발작적 운동실조증 치료 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 발작적 운동실조증 치료 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 모세혈관확장성 운동실조증
- 발작성 운동실조증
- 척수 소뇌 실조증
- 프리드리히 운동실조증
- 기타 유형
- 세계의 발작적 운동실조증 치료 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 의약품
- Levodopa
- Pramipexole
- Venlafaxine
- 기타 치료법
- 세계의 발작적 운동실조증 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 비경구
- 기타 투여 경로
- 세계의 발작적 운동실조증 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 직접 입찰
- 소매 판매량
- 기타 유통 채널
- 세계의 발작적 운동실조증 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 클리닉
- 재택 헬스케어
- 기타 최종사용자
- 세계의 발작적 운동실조증 치료 시장, 모세혈관확장성 운동실조증의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 면역 조절 치료
- 항산화 요법
- 유전자 치료
- 세계의 발작적 운동실조증 치료 시장, 발작성 운동실조증의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 약제(Acetazolamide, Phenytoin)
- 대증요법(벤조디아제핀)
- 세계의 발작적 운동실조증 치료 시장, 척수 소뇌 실조증 병형별 서브 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 치료(항우울제, 항경련약)
- 물리 치료
- 유전자 치료
- 세계의 발작적 운동실조증 치료 시장, 프리드리히 운동실조증 병형별 서브 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 항산화 요법(이데베논)
- 유전자 치료
- 치료(심장약, 물리 치료)
- 세계의 발작적 운동실조증 치료 시장, 기타 유형의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 치료(근이완약, 도파민 작용제)
- 지지요법(물리 치료, 작업치료)
제7장 지역별·국가별 분석
- 세계의 발작적 운동실조증 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 발작적 운동실조증 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 발작적 운동실조증 치료 시장 : 경쟁 구도
- 발작적 운동실조증 치료 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Sanofi Overview, Products and Services, Strategy and Financial Analysis
- Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- Takeda Pharmaceutical Company Limited
- Merck KGaA
- Banner Health
- Astellas Pharma Inc.
- Daiichi Sankyo Company Limited
- UCB S.A.
- Ipsen
- BioMarin Pharmaceutical Inc.
- Neurocrine Biosciences Inc.
- PTC Therapeutics Inc.
- Kissei Pharmaceutical Co. Ltd.
- Catalyst Pharmaceuticals Inc.
- Design Therapeutics Inc.
- Larimar Therapeutics Inc.
- Voyager Therapeutics Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 발작적 운동실조증 치료 시장 2029 : 새로운 기회를 제공하는 국가
- 발작적 운동실조증 치료 시장 2029 : 새로운 기회를 제공하는 부문
- 발작적 운동실조증 치료 시장 2029 : 성장 전략
제36장 부록
KSA
Treatment for episodic ataxia encompasses medical strategies aimed at managing and alleviating the symptoms of this rare neurological disorder, which features intermittent episodes of poor coordination, balance issues, and sometimes vertigo. The approach includes medications, therapies, and lifestyle changes designed to control symptoms and enhance the quality of life for those affected.
The main treatment categories for episodic ataxia include ataxia telangiectasia, episodic ataxia, spinocerebellar ataxia, and Friedreich's ataxia. Ataxia telangiectasia is a rare genetic disorder impacting both the nervous and immune systems, leading to progressive movement difficulties, an elevated risk of cancer, and other health concerns. Treatments for this condition may involve medications such as levodopa, pramipexole, and venlafaxine, administered through various methods including oral and parenteral routes. Distribution channels for these treatments include direct tenders and retail sales, serving different end users through these channels.
The episodic ataxia treatment market research report is one of a series of new reports from The Business Research Company that provides episodic ataxia treatment market statistics, including episodic ataxia treatment industry global market size, regional shares, competitors with an episodic ataxia treatment market share, detailed episodic ataxia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the episodic ataxia treatment industry. This episodic ataxia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The episodic ataxia treatment market size has grown strongly in recent years. It will grow from $11.07 billion in 2024 to $11.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to an increasing understanding of genetic causes, increasing funding for rare disease research, increasing availability of specialized clinics, rising awareness of personalized medicine, and growth in clinical trial participation.
The episodic ataxia treatment market size is expected to see strong growth in the next few years. It will grow to $15.21 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing genetic testing accessibility, rising demand for genetic counseling services, growing number of clinical trials, increasing number of patient registries, and increasing investment in rare disease biobanks. Major trends in the forecast period include technological advancements, personalized medicine, telemedicine, stem cell therapy, and telerehabilitation services.
The growing prevalence of neurological disorders is anticipated to drive the expansion of the episodic ataxia treatment market. Neurological disorders encompass diseases affecting the central and peripheral nervous systems, including the brain, spinal cord, cranial and peripheral nerves, autonomic nervous system, nerve roots, neuromuscular junction, and muscles. Factors such as an aging population, genetic predispositions, and infectious diseases contribute to the rising incidence of neurological disorders. Episodic ataxia treatment aims to address symptoms and enhance the management of conditions involving intermittent coordination and balance loss. For example, in April 2022, the European Brain Council, a Belgium-based non-profit organization, reported that Dementia (a progressive neurological disorder) impacted 10.5 million people in Europe in 2022, with projections indicating an increase to 18.7 million by 2050. Consequently, the rising prevalence of neurological disorders is fueling the episodic ataxia treatment market.
Leading companies in the episodic ataxia treatment market are prioritizing the development of innovative solutions, such as treatments for Friedreich's ataxia (FA), to improve patient outcomes and address the unmet needs of this rare neurological condition. Episodic ataxia (EA) is characterized by sporadic episodes of ataxia and a lack of voluntary muscle coordination, with episodes varying in duration, frequency, and severity. For instance, in February 2024, Biogen Inc., a US-based biotechnology company, announced the approval of SKYCLARYS (omaveloxolone) for treating Friedreich's ataxia (FA). Omaveloxolone targets the underlying mitochondrial dysfunction associated with FA, potentially altering disease progression rather than merely alleviating symptoms. The therapy functions as a potent transcriptional modulator, aiding in the restoration of mitochondrial function and cellular energy production.
In November 2022, Kriya Therapeutics Inc., a US-based biopharmaceutical company, acquired Redpin Therapeutics Inc. for an undisclosed amount. This acquisition aims to significantly bolster Kriya Therapeutics' neurology pipeline by incorporating Redpin's innovative treatments for neurological disorders into its existing gene therapy portfolio. Redpin Therapeutics Inc. is a US-based company dedicated to developing treatments for various neurological and neurodegenerative disorders, including episodic ataxia.
Major companies operating in the episodic ataxia treatment market are Pfizer Inc., AbbVie Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Merck KGaA, Banner Health, Astellas Pharma Inc., Daiichi Sankyo Company Limited, UCB S.A., Ipsen, BioMarin Pharmaceutical Inc., Neurocrine Biosciences Inc., PTC Therapeutics Inc., Kissei Pharmaceutical Co. Ltd., Catalyst Pharmaceuticals Inc., Design Therapeutics Inc., Larimar Therapeutics Inc., Voyager Therapeutics Inc., Capsida Biotherapeutics Inc., Adverum Biotechnologies Inc., CRISPR Therapeutics AG
North America was the largest region in the episodic ataxia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the episodic ataxia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the episodic ataxia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The episodic ataxia treatment market consists of revenues earned by entities by providing services such as genetic counseling, physical therapy, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The episodic ataxia treatment market also includes sales of antiepileptic drugs, beta-blockers, genetic testing kits, and wearable health monitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Episodic Ataxia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on episodic ataxia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for episodic ataxia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The episodic ataxia treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Ataxia telangiectasia; Episodic ataxia; Spinocerebellar ataxia; Friedreich's ataxia; Other Types
- 2) By Treatment: Medications; Levodopa; Pramipexole; Venlafaxine; Other Treatments
- 3) By Route of Administration: Oral; Parenteral; Other Routes of Administration
- 4) By Distribution Channel: Direct Tender; Retail Sales; Other Distribution Channels
- 5) By End User: Hospital; Clinics; Home Healthcare; Other End Users
Subsegments
- 1) By Ataxia Telangiectasia: Neurological Complications; Immunodeficiency; Cancer Susceptibility
- 2) By Episodic Ataxia: Type 1 (EA1); Type 2 (EA2); Other Subtypes
- 3) By Spinocerebellar Ataxia: Type 1 (SCA1); Type 2 (SCA2); Type 3 (SCA3); Type 6 (SCA6); Type 7 (SCA7); Type 17 (SCA17); Other Types
- 4) By Friedreich's Ataxia: Early-onset Friedreich's Ataxia; Late-onset Friedreich's Ataxia; Other Types
- 5) By Other Treatments: Supportive Care (Physical Therapy, Occupational Therapy); Symptomatic Treatment (Muscle Relaxants, Dopaminergic Medications)
- Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Sanofi; Bristol-Myers Squibb Company; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Episodic Ataxia Treatment Market Characteristics
3. Episodic Ataxia Treatment Market Trends And Strategies
4. Episodic Ataxia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Episodic Ataxia Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Episodic Ataxia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Episodic Ataxia Treatment Market Growth Rate Analysis
- 5.4. Global Episodic Ataxia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Episodic Ataxia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Episodic Ataxia Treatment Total Addressable Market (TAM)
6. Episodic Ataxia Treatment Market Segmentation
- 6.1. Global Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ataxia Telangiectasia
- Episodic Ataxia
- Spinocerebullar Ataxia
- Friedreich's Ataxia
- Other Types
- 6.2. Global Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medications
- Levodopa
- Pramipexole
- Venlafaxine
- Other Treatments
- 6.3. Global Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Routes Of Administration
- 6.4. Global Episodic Ataxia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Direct Tender
- Retail Sales
- Other Distribution Channels
- 6.5. Global Episodic Ataxia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital
- Clinics
- Home Healthcare
- Other End Users
- 6.6. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Ataxia Telangiectasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunomodulatory Treatments
- Antioxidant Therapy
- Gene Therapy
- 6.7. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Episodic Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medications (Acetazolamide, Phenytoin)
- Symptomatic Treatments (Benzodiazepines)
- 6.8. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Spinocerebellar Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Symptomatic Treatment (Antidepressants, Anticonvulsants)
- Physical Therapy
- Gene Therapy
- 6.9. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Friedreich's Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antioxidant Therapy (Idebenone)
- Gene Therapy
- Symptomatic Treatment (Cardiac Medications, Physical Therapy)
- 6.10. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Symptomatic Treatment (Muscle Relaxants, Dopaminergic Medications)
- Supportive Care (Physical Therapy, Occupational Therapy)
7. Episodic Ataxia Treatment Market Regional And Country Analysis
- 7.1. Global Episodic Ataxia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Episodic Ataxia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Episodic Ataxia Treatment Market
- 8.1. Asia-Pacific Episodic Ataxia Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Episodic Ataxia Treatment Market
- 9.1. China Episodic Ataxia Treatment Market Overview
- 9.2. China Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Episodic Ataxia Treatment Market
- 10.1. India Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Episodic Ataxia Treatment Market
- 11.1. Japan Episodic Ataxia Treatment Market Overview
- 11.2. Japan Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Episodic Ataxia Treatment Market
- 12.1. Australia Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Episodic Ataxia Treatment Market
- 13.1. Indonesia Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Episodic Ataxia Treatment Market
- 14.1. South Korea Episodic Ataxia Treatment Market Overview
- 14.2. South Korea Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Episodic Ataxia Treatment Market
- 15.1. Western Europe Episodic Ataxia Treatment Market Overview
- 15.2. Western Europe Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Episodic Ataxia Treatment Market
- 16.1. UK Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Episodic Ataxia Treatment Market
- 17.1. Germany Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Episodic Ataxia Treatment Market
- 18.1. France Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Episodic Ataxia Treatment Market
- 19.1. Italy Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Episodic Ataxia Treatment Market
- 20.1. Spain Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Episodic Ataxia Treatment Market
- 21.1. Eastern Europe Episodic Ataxia Treatment Market Overview
- 21.2. Eastern Europe Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Episodic Ataxia Treatment Market
- 22.1. Russia Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Episodic Ataxia Treatment Market
- 23.1. North America Episodic Ataxia Treatment Market Overview
- 23.2. North America Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Episodic Ataxia Treatment Market
- 24.1. USA Episodic Ataxia Treatment Market Overview
- 24.2. USA Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Episodic Ataxia Treatment Market
- 25.1. Canada Episodic Ataxia Treatment Market Overview
- 25.2. Canada Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Episodic Ataxia Treatment Market
- 26.1. South America Episodic Ataxia Treatment Market Overview
- 26.2. South America Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Episodic Ataxia Treatment Market
- 27.1. Brazil Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Episodic Ataxia Treatment Market
- 28.1. Middle East Episodic Ataxia Treatment Market Overview
- 28.2. Middle East Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Episodic Ataxia Treatment Market
- 29.1. Africa Episodic Ataxia Treatment Market Overview
- 29.2. Africa Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Episodic Ataxia Treatment Market Competitive Landscape And Company Profiles
- 30.1. Episodic Ataxia Treatment Market Competitive Landscape
- 30.2. Episodic Ataxia Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Episodic Ataxia Treatment Market Other Major And Innovative Companies
- 31.1. Takeda Pharmaceutical Company Limited
- 31.2. Merck KGaA
- 31.3. Banner Health
- 31.4. Astellas Pharma Inc.
- 31.5. Daiichi Sankyo Company Limited
- 31.6. UCB S.A.
- 31.7. Ipsen
- 31.8. BioMarin Pharmaceutical Inc.
- 31.9. Neurocrine Biosciences Inc.
- 31.10. PTC Therapeutics Inc.
- 31.11. Kissei Pharmaceutical Co. Ltd.
- 31.12. Catalyst Pharmaceuticals Inc.
- 31.13. Design Therapeutics Inc.
- 31.14. Larimar Therapeutics Inc.
- 31.15. Voyager Therapeutics Inc.
32. Global Episodic Ataxia Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Episodic Ataxia Treatment Market
34. Recent Developments In The Episodic Ataxia Treatment Market
35. Episodic Ataxia Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Episodic Ataxia Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Episodic Ataxia Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Episodic Ataxia Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
